High-risk smoldering Multiple Myeloma
Showing 1 - 25 of >10,000
Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM) Trial (Linvoseltamab)
Not yet recruiting
- Monoclonal Gammopathy of Undetermined Significance (MGUS)
- Smoldering Multiple Myeloma (SMM)
- (no location specified)
Nov 17, 2023
Multiple Myeloma Trial run by the National Cancer Institute (NCI) (Dexamethasone, Carfilzomib, Daratumumab)
Recruiting
- Multiple Myeloma
- Dexamethasone
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 23, 2023
Multiple Myeloma, High Risk Smoldering Multiple Myeloma Trial in United States (Ixazomib (MLN9708), Dexamethasone)
Active, not recruiting
- Multiple Myeloma
- High Risk Smoldering Multiple Myeloma
- Ixazomib (MLN9708)
- Dexamethasone
-
Basking Ridge, New Jersey
- +5 more
Nov 15, 2022
Multiple Myeloma, Smoldering Multiple Myeloma Trial in Oslo (TG01)
Not yet recruiting
- Multiple Myeloma
- Smoldering Multiple Myeloma
- TG01
-
Oslo, NorwayOslo Myeloma Center
May 2, 2023
High-risk Smoldering Multiple Myeloma, Smoldering Multiple Myeloma, Multiple Myeloma Trial in Boston (Teclistamab, Lenalidomide,
Recruiting
- High-risk Smoldering Multiple Myeloma
- +2 more
- Teclistamab
- +2 more
-
Boston, MassachusettsDana Farber Cancer Institute
Aug 11, 2022
Myeloma Trial in Houston (Belantamab mafodotin)
Recruiting
- Myeloma
- Belantamab mafodotin
-
Houston, TexasM D Anderson Cancer Center
Jul 9, 2022
Smoldering Plasma Cell Myeloma Trial in Houston (Laboratory Biomarker Analysis, Pembrolizumab)
Active, not recruiting
- Smoldering Plasma Cell Myeloma
- Laboratory Biomarker Analysis
- Pembrolizumab
-
Houston, TexasM D Anderson Cancer Center
Mar 23, 2022
Smoldering Multiple Myeloma (SMM) Trial (Linvoseltamab)
Not yet recruiting
- Smoldering Multiple Myeloma (SMM)
- (no location specified)
Jul 13, 2023
Multiple Myeloma Trial in Miami (Teclistamab, Talquetamab, Daratumumab SC)
Not yet recruiting
- Multiple Myeloma
- Teclistamab
- +2 more
-
Miami, FloridaUniversity of Miami
Oct 20, 2023
Multiple Myeloma, Smoldering Multiple Myeloma Trial in Boston (Ciltacabtagene Autoleucel, Cyclophosphamide, Fludarabine
Not yet recruiting
- Multiple Myeloma
- Smoldering Multiple Myeloma
- Ciltacabtagene Autoleucel
- +2 more
-
Boston, MassachusettsDana Farber Cancer Institute
Mar 2, 2023
High-risk Smoldering Multiple Myeloma, Multiple Myeloma Trial in Boston (Daratumumab, Bortezomib, Lenalidomide)
Recruiting
- High-risk Smoldering Multiple Myeloma
- Multiple Myeloma
- Daratumumab
- +3 more
-
Boston, Massachusetts
- +1 more
Oct 18, 2021
Smoldering Multiple Myeloma Trial in Boston (Nivolumab, Lenalidomide, Dexamethasone)
Suspended
- Smoldering Multiple Myeloma
- Nivolumab
- +2 more
-
Boston, MassachusettsDana Farber Cancer Institute
Jan 4, 2022
Smoldering Multiple Myeloma Trial in United States (Carfilzomib, Lenalidomide, Daratumumab)
Active, not recruiting
- Smoldering Multiple Myeloma
- Carfilzomib
- +3 more
-
Tampa, Florida
- +9 more
Jul 8, 2022
Smoldering Myeloma, Smoldering Multiple Myeloma Trial in United States (Elotuzumab, Lenalidomide, Dexamethasone)
Active, not recruiting
- Smoldering Myeloma
- Smoldering Multiple Myeloma
- Elotuzumab
- +2 more
-
Denver, Colorado
- +8 more
Nov 1, 2021
High Risk Smoldering Multiple Myeloma Trial in New York (Ibrutinib)
Terminated
- High Risk Smoldering Multiple Myeloma
-
New York, New YorkIcahn School of Medicine at Mount Sinai
Nov 18, 2020
Monoclonal Gammopathy, Smoldering Multiple Myeloma Trial in United States (Daratumumab)
Active, not recruiting
- Monoclonal Gammopathy
- Smoldering Multiple Myeloma
-
Monterey, California
- +5 more
Nov 1, 2021
Multiple Myeloma Trial in Austria, Germany, Israel (Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA], Placebo 1.7 ml
Active, not recruiting
- Multiple Myeloma
- Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
- Placebo 1.7 ml Subcutaneous Solution
-
Graz, Austria
- +9 more
Aug 24, 2022
Smoldering Multiple Myeloma Trial in Spain (carfilzomib, Lenalidomide, Dexamethasone)
Active, not recruiting
- Smoldering Multiple Myeloma
- carfilzomib
- +3 more
-
Barcelona, Spain
- +15 more
Feb 15, 2021
Smoldering Multiple Myeloma Trial in Rochester (Denosumab)
Active, not recruiting
- Smoldering Multiple Myeloma
-
Rochester, New YorkUniversity of Rochester
Oct 3, 2022
Smoldering Multiple Myeloma Trial in Boston (Ixazomib, Lenalidomide, Dexamethasone)
Active, not recruiting
- Smoldering Multiple Myeloma
- Ixazomib
- +2 more
-
Boston, MassachusettsDana Farber Cancer Institute
Mar 15, 2022
Prostate Cancer, Multiple Myeloma, Smoldering Multiple Myeloma (SMM) Trial in Rochester (Curcumin plus Piperine)
Recruiting
- Prostate Cancer
- +3 more
- Curcumin plus Piperine
-
Rochester, New YorkUniversity of Rochester
Jun 17, 2022
Multiple Myeloma, Smoldering Trial in United States (Omega-3, Curcumin, Probiotic)
Recruiting
- Multiple Myeloma, Smoldering
- Omega-3
- +3 more
-
Basking Ridge, New Jersey
- +6 more
Oct 1, 2023